ArticleHuman vaccines & immunotherapeutics2025
Specificity and functional humoral immune responses induced by the VBI-1501A eVLP HCMV gB vaccine compared to the gB/MF59 vaccine.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progress and prospects for herpesvirus vaccination using gB antigens.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) is the leading infectious cause of birth defects globally yet has no licensed vaccine. Though some HCMV glycoprotein B (gB)-based vaccine candidates, such as the MF59-adjuvanted gB vaccine (gB/MF59) elicited limited virus neutralization, enveloped virus-like particle (eVLP) expression of gB induced robust CMV-neutralizing antibodies in a phase I trial in CMV-seronegative participants. Here, we further characterize the anti-gB binding and functional antibody responses induced by the VBI1501A gB eVLP vaccine in comparison to gB/MF59, the leading clinically tested vaccine to date. VBI1501A vaccination induced higher IgG binding to antigenic domains (AD) that are neutralizing antibody targets, AD-4 and AD-4+5, compared to the gB/MF59 vaccine, but elicited lower IgG binding to gB full-length and ectodomain. VBI1501A-elicited IgG responses showed no binding to the linear neutralizing domain AD-2 and elicited minimal binding to the AD-6 domain associated with viral cell-associated spread. While VBI1501A did not elicit IgG that bound to the clade-matched strain nor antibody-dependent cellular cytotoxicity responses, plasma IgG binding to cell associated gB and antibody dependent cellular phagocytosis responses were higher compared to the gB/MF59 vaccine. This study offers insight into strategies to improve on vaccine design of partially successful gB-containing HCMV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.